These findings are significant as they may explain why despite promising data, PAF antagonists have previously failed to exhibit clinical benefit in clinical trials relating to PAF-mediated inflammation in sepsis, acute pancreatitis, and asthma [171,296,297,298]. This evidence concerns the gene PCLAF and asthma.